Apalutamide-associated rash combined with severe neutropenia and eosinophilia: a case report.

ABSTRACT:

Background

Apalutamide is approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). Currently, the incidence of rash is higher in patients treated with apalutamide. However, the occurrence of apalutamide-associated skin rash combined with apalutamide-induced neutropenia and eosinophilia in a single patient has not been reported previously. The aim of this study is to describe a rare and severe adverse reaction induced by apalutamide, in order to improve clinical awareness and facilitate early recognition and management. Here, we report a case of an mHSPC patient treated with apalutamide who experienced grade 3 rash combined with severe neutropenia and eosinophilia.

Case description

A 74

SUBMITTER: Shao Y 

PROVIDER: S-EPMC12319624 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature